autologous ebv specific cytotoxic t lymphocytes
Cell therapyexperimental
Clinical trial activity
13 trials · 11 clinical orgs · 0 marketing orgs
Phase 1
10
Phase 2
5
Phase 3
1
Phase 4
0
Earliest trial started May 1, 1993 (NCT00058812)
Timeline
Indications
Studied for
- Adenoviridae · Phase 1/Phase 2
- Burkitt Lymphoma · Phase 2
- Cytomegalovirus Infections · Phase 1/Phase 2
- Epstein-Barr Virus Infections · Phase 1/Phase 2
- Hodgkin Disease · Phase 1
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Lymphoma · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Lymphoproliferative Disorders · Phase 1
- Nasopharyngeal Carcinoma · Phase 3
- Nasopharyngeal Neoplasms · Phase 1
- Neoplasms · Phase 2
Mechanism of action
- T-lymphocytesSupplementation
T-lymphocytes supplementation
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- autologous ebv-ctls
- autologous ebv specific cytotoxic t lymphocytes
- ebv specific ctl
- ebv specific ctls
- ebv-specific ctls
- ebv specific t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06909110 | Phase 1/Phase 2 (Phase 2) | Apr 30, 2025 | Stanford University |
| NCT04364178 | Phase 1/Phase 2 (Phase 2) | Jun 1, 2020 | University of Pittsburgh |
| NCT03648697 | Phase 2 | Oct 10, 2018 | China Immunotech, Fujian Medical University |
| NCT02578641 | Phase 3 | Jul 1, 2014 | Government of Singapore, Tessa Therapeutics |
| NCT01498484 | Phase 2 | Dec 1, 2011 | Atara Biotherapeutics, Cornell University |
| NCT00709033 | Phase 1 | Jul 1, 2009 | Baylor University, Methodist Cancer Center, Houston, Texas |
| NCT00706316 | Phase 1 | Dec 1, 2007 | University of Toronto |
| NCT00082225 | Phase 1 | Oct 1, 2003 | Baylor University, Methodist Cancer Center, Houston, Texas |
| NCT00078546 | Phase 1 | Sep 1, 2003 | Baylor University, Methodist Cancer Center, Houston, Texas |
| NCT00058604 | Phase 1 | Jan 1, 2001 | Baylor University, Methodist Cancer Center, Houston, Texas |
| NCT00058591 | Phase 1 | Jan 1, 2000 | Baylor University, Methodist Cancer Center, Houston, Texas |
| NCT00058617 | Phase 1 | Jan 1, 1996 | Baylor University, Methodist Cancer Center, Houston, Texas |
| NCT00058812 | Phase 1 | May 1, 1993 | Baylor University, Methodist Cancer Center, Houston, Texas |
Showing 13 of 13 trials
Page 1 / 1
Organizations
Research & Development (11)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Baylor University | Academic/Hospital | 7 | 7 | 1 | 1993 |
| Methodist Cancer Center, Houston, Texas | Academic/Hospital | 7 | 0 | 1 | 1993 |
| Atara Biotherapeutics | For profit | 1 | 1 | 1 | 2011 |
| China Immunotech | For profit | 1 | 0 | 1 | 2018 |
| Cornell University | Academic/Hospital | 1 | 0 | 1 | 2011 |
| Fujian Medical University | Academic/Hospital | 1 | 1 | 1 | 2018 |
| Government of Singapore | Government | 1 | 0 | 1 | 2014 |
| Stanford University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Tessa Therapeutics | For profit | 1 | 1 | 1 | 2014 |
| University of Pittsburgh | Academic/Hospital | 1 | 1 | 1 | 2020 |
| University of Toronto | Academic/Hospital | 1 | 1 | 1 | 2007 |
11 organizations
Page 1 / 1